ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
BriaCell Therapeutics Corporation

BriaCell Therapeutics Corporation (BCTX)

0.4028
-0.0291
(-6.74%)
Closed January 11 3:00PM
0.4067
0.0039
(0.97%)
After Hours: 6:22PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.4067
Bid
0.40
Ask
0.4068
Volume
1,087,446
0.38 Day's Range 0.436
0.395 52 Week Range 4.89
Market Cap
Previous Close
0.4319
Open
0.436
Last Trade
10
@
0.4067
Last Trade Time
Financial Volume
US$ 439,963
VWAP
0.404583
Average Volume (3m)
1,505,809
Shares Outstanding
35,838,161
Dividend Yield
-
PE Ratio
-79.28
Earnings Per Share (EPS)
-0.13
Revenue
-
Net Profit
-4.79M

About BriaCell Therapeutics Corporation

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination... BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers. Show more

Sector
Aircraft
Industry
Business Services, Nec
Headquarters
Vancouver, British Columbia, Can
Founded
2009
BriaCell Therapeutics Corporation is listed in the Aircraft sector of the NASDAQ with ticker BCTX. The last closing price for BriaCell Therapeutics was US$0.43. Over the last year, BriaCell Therapeutics shares have traded in a share price range of US$ 0.395 to US$ 4.89.

BriaCell Therapeutics currently has 35,838,161 shares outstanding. The market capitalization of BriaCell Therapeutics is US$15.48 million. BriaCell Therapeutics has a price to earnings ratio (PE ratio) of -79.28.

BCTX Latest News

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โ€œBriaCellโ€ or the โ€œCompanyโ€), a clinical-stage...

BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. (โ€œBriaProโ€ or the โ€œCompanyโ€), a pre-clinical stage immunotherapy company developing binding agents and...

BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โ€œBriaCellโ€ or the โ€œCompanyโ€), a clinical-stage...

BriaCell 2024 SABCSยฎ Poster Highlights Ability of Bria-IMTโ„ข Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

BriaCell reports influx of cancer fighting CD8+ โ€œkillerโ€ T cell into metastatic breast cancer tumors and lymph organs turning โ€œColdโ€ tumors and lymph nodes โ€œHotโ€ on ImmunoPET imaging in cancer...

BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โ€œBriaCellโ€ or the โ€œCompanyโ€), a clinical-stage...

BriaCell Therapeutics Announces Proposed Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โ€œBriaCellโ€ or the โ€œCompanyโ€), a clinical-stage...

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCSยฎ

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the...

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCellโ€™s pivotal Phase 3 study of Bria-IMTโ„ข plus an immune check point inhibitor in metastatic...

BriaCell 2024 SABCSยฎ Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

SABCSยฎ โ€œSpotlightโ€ poster to be presented on Wednesday, December 11, 2024 7:00 AM โ€“ 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer...

BriaCell Provides Update to its Board of Directors

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โ€œBriaCellโ€ or the โ€œCompanyโ€), a clinical-stage...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.183152-31.05050080360.5898520.650.39519156540.47721372CS
4-0.2723-40.10309278350.6790.6790.39513478140.55624402CS
12-0.4125-50.35400390620.81921.260.39515058090.80105868CS
26-0.6533-61.63207547171.061.960.39531223730.72932097CS
52-4.4133-91.56224066394.824.890.39516324660.78048004CS
156-7.7933-95.04024390248.212.090.3957557512.56731295CS
260-3.8333-90.40801886794.2412.470.39511463664.48906458CS

BCTX - Frequently Asked Questions (FAQ)

What is the current BriaCell Therapeutics share price?
The current share price of BriaCell Therapeutics is US$ 0.4067
How many BriaCell Therapeutics shares are in issue?
BriaCell Therapeutics has 35,838,161 shares in issue
What is the market cap of BriaCell Therapeutics?
The market capitalisation of BriaCell Therapeutics is USD 15.48M
What is the 1 year trading range for BriaCell Therapeutics share price?
BriaCell Therapeutics has traded in the range of US$ 0.395 to US$ 4.89 during the past year
What is the PE ratio of BriaCell Therapeutics?
The price to earnings ratio of BriaCell Therapeutics is -79.28
What is the reporting currency for BriaCell Therapeutics?
BriaCell Therapeutics reports financial results in USD
What is the latest annual profit for BriaCell Therapeutics?
The latest annual profit of BriaCell Therapeutics is USD -4.79M
What is the registered address of BriaCell Therapeutics?
The registered address for BriaCell Therapeutics is SUITE 300 - 235 WEST 15TH STREET, VANCOUVER, BRITISH COLUMBIA, V7T 2X1
What is the BriaCell Therapeutics website address?
The website address for BriaCell Therapeutics is www.briacell.com
Which industry sector does BriaCell Therapeutics operate in?
BriaCell Therapeutics operates in the BUSINESS SERVICES, NEC sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VRMEVerifyMe Inc
US$ 2.57
(52.98%)
57.83M
WKEYWISeKey International Holdings AG
US$ 10.041
(52.83%)
6.72M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
INTZIntrusion Inc
US$ 2.8888
(44.44%)
40.61M
IGMSIGM Biosciences Inc
US$ 2.095
(-66.21%)
5.81M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
US$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
US$ 0.420501
(-47.76%)
7.85M
MRSNMersana Therapeutics Inc
US$ 0.691
(-46.85%)
58.44M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
US$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
US$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
US$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M

BCTX Discussion

View Posts
Monksdream Monksdream 4 days ago
BCTX, new 52 week low
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 1 month ago
BCTX: It's actually GREEN now in price!!! (Heck, maybe there IS a "God" --- of WOMEN, hopefully!!!! And NOT some clown nailed to a cross in Naples, Italy, 2K years ago!!!!)

๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 1 month ago
BCTX: I sincerely HOPE that this BCTX stock --- with GREAT news for Women's BREAST Cancer concerns --- gets monster short-SQUEEZED, like below!!! Metaphorically speaking, that is.)

๐Ÿ‘๏ธ0
shurtha2000 shurtha2000 1 month ago
Slow and Steady up
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 1 month ago
BCTX: The Markets simply do NOT give-a-fluck about WOMEN's issues of any sort!!! (BCTX could have PR'd that they have outright CURED all Breast Cancers, but this stock STILL would not have soared in price!!!)
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 1 month ago
BCTX: The only worrisome thing about anything (Medical) WOMEN's STUFF, is that they rarely if ever SOAR in price. (While mere FLUFF news about anything MEN's Medical issues --- like today's @CADL baloney PR -- often SOAR in price gloriously.)
๐Ÿ‘๏ธ0
axelvento axelvento 1 month ago
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting the study
Median OS of 13.7 months in breast cancer patients with central nervous system (CNS) metastasis treated with the Bria-IMT™ regimen alone or in combination with an immune check point inhibitor (CPI)
Five BriaCell posters (four today and one on Dec 13 th ) showcase robust survival and clinical benefit data, plus key biomarker data from Phase 2 trial of Bria-IMT™ in metastatic breast cancer (MBC)
Biomarkers identify patients who benefit from treatments with the Bria-IMT™ regimen
No toxicity related discontinuations



https://feeds.issuerdirect.com/news-release.html?newsid=7743652450762128
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 1 month ago
BCTX: Much more IMPRESSIVE stats. for this BCTX news --- vs. the baloney stats. for @CADL's Prostate Cancer results, which were in truth mere STATISTICAL ARTIFACTS and, as such, significant of NOTHING!!
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 month ago
BCTX OUT ON NEWS
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 month ago
BCTX MASSIVE NEWS FOR THIS CANADIAN BIO
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 month ago
BCTX BLOWING UP
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 month ago
BCTX PUSHING TO TOP OF THE DAILY CLOUD VERY NICE
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 month ago
BCTX..............................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 month ago
BCTX NICE CANADIAN BIO READY FOR A DOLLAR
๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 months ago
BCTX.........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
axelvento axelvento 3 months ago
HUGE$ In BriaCell's Phase 2 clinical study, patients treated with the same Bria-IMT™ regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% (i.e. 55% of patients remain alive at least one year after starting on the study). This rate exceeds the survival data of the current standard of care for similar patients (see Table 1). Notably, 4 of 13 patients recruited in 2022 remain in survival follow-up as well, including:

Patient 01-009: Overall survival (OS) of 25 months has been reported in a patient who had failed 6 prior treatments prior to the BriaCell regimen. Stable disease and lymph node shrinkage has been recorded during 13 cycles of therapy.
Patient 07-001: OS of 24 months. She had stable disease and received 8 cycles of BriaCell's therapy.
Patient 16-003: OS of 15 months and received 8 cycles of therapy with stable disease. Prior to the BriaCell regimen, she had 7 lines of therapy, which included the progression of disease while on the antibody-drug conjugate (ADC) Enhertu.
Patient 11-018: OS of 14 months. This previously-reported responder with 100% resolution of her brain metastasis has recently completed her 19th cycle of therapy.
👍️ 1 ✌️ 1
stocktowatch stocktowatch 3 months ago
$BCTX No serious adverse events related to Bria-IMT™, 35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™, Pivotal Phase 3 study patient enrollment completion is expected in mid-2025

BIG NEWS https://feeds.issuerdirect.com/news-release.html?newsid=7546332967366263
👍 1
glenn1919 glenn1919 3 months ago
BCTX...........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 months ago
BCTX.........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Awl416 Awl416 3 months ago
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with โ€œEye-Bulgingโ€ Tumor
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 3 months ago
wainwright issues buy on bctx with $15 price $$$$$$$$$$$ cure 4 breast cancer? and others
๐Ÿ‘๏ธ0
1hot toddy 1hot toddy 3 months ago
Now the co has 8.5 mil for their business plan. Great for co. U got out and missed the push up as co has cure for breast cancer. Stock will rock
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 months ago
BCTX........................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
tw0122 tw0122 4 months ago
Gets out now millions of offering shares at .69โ€ฆ12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross proceeds of approximately $8.5 million,
👎️ 1
glenn1919 glenn1919 4 months ago
BCTX..................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Awl416 Awl416 4 months ago
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
👍 1
boston127 boston127 4 months ago
Sorry. Wrong Board.
๐Ÿ‘๏ธ0
Awl416 Awl416 4 months ago
BriaCell Therapeutics Announces $8.5 Million Offering
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 4 months ago
aks yourself why no BP wanted to be a part of this. Plenty of time to notice?
๐Ÿ‘๏ธ0
glenn1919 glenn1919 4 months ago
BCTX..........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
S3lfMade S3lfMade 4 months ago
I'm predicting an offering this week... Company needs cash. Under $1m currently
๐Ÿ‘๏ธ0
subslover subslover 4 months ago
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor
OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature
Ongoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer population
No drug related discontinuations to date
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โ€œBriaCellโ€ or the โ€œCompanyโ€), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer.
https://www.otcmarkets.com/stock/BCTX/news/story?e&id=2978177
๐Ÿ‘๏ธ0
Awl416 Awl416 4 months ago
Donโ€™t blink
๐Ÿ‘๏ธ0
Awl416 Awl416 4 months ago
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
๐Ÿ‘๏ธ0
dabonenose dabonenose 4 months ago
Good news and it goes lower again,,,lol
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
BCTX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
BCTX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
BCTX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
BCTX under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
BCTX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
BCTX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
BCTX. Under $3
๐Ÿ‘๏ธ0
QuicKtip QuicKtip 9 months ago
$BCTX Shows โ€œStrong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancerโ€

Press Release: https://bit.ly/4aJmAoc

$BCTX #CancerTreatment #Innovation
๐Ÿ‘๏ธ0
BigHeis BigHeis 10 months ago
Does anyone have information about the stock spinoff that occurred last year with this company? I have 600 shares of the spinoff security with 0 value and has remained that way since the spinoff. Thanksโ€ฆ
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
BCTX new 52 lo
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
BCTX new 52 lo
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
BCTX 10Q due March 13
๐Ÿ‘๏ธ0
Monksdream Monksdream 11 months ago
BCTX new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 11 months ago
BCTX new 52 week low
๐Ÿ‘๏ธ0
QuicKtip QuicKtip 1 year ago
$BCTX is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. https://finance.yahoo.com/news/briacell-records-responder-remarkable-improvement-120000404.html
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock